Elan Corporation plc - Articles and news items

Biogen Idec logo

Biogen Idec to acquire full rights and control of TYSABRI® from Elan for upfront cash and contingent payments

Industry news, News / 6 February 2013 / Biogen Idec

Biogen Idec has agreed to purchase Elan’s interest in TYSABRI…

Biogen Idec logo

Biogen Idec and Elan submit applications for first-line use of TYSABRI in anti-JCV antibody negative patients with MS

Industry news, News / 16 January 2013 / Biogen Idec

Biogen Idec and Elan have submitted applications to the U.S. FDA…

Biogen Idec logo

TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS

Industry news, News / 11 October 2012 / Biogen Idec

Results from 11 company-sponsored TYSABRI presentations…

Elan logo

Elan appoints Hans Peter Hasler as Chief Operating Officer

Industry news, News / 24 September 2012 / Elan Corporation

Mr. Hasler is currently a non-executive director of the Company and he will retire from the board of directors of the Company…

Biogen Idec logo

New analysis of risk stratification for TYSABRI® published in New England Journal of Medicine

Industry news, News / 18 May 2012 / Biogen Idec / Elan Corporation plc

Use of biomarker has potential to advance personalised treatment for MS patients…

Biogen Idec logo

ASCEND study to evaluate the effectiveness of TYSABRI® (natalizumab) as a treatment for SPMS

Industry news, News / 26 January 2012 / Biogen Idec

Biogen Idec and Elan Corporation, plc announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for SPMS…

Biogen Idec logo

FDA updates TYSABRI(R) (NATALIZUMAB) label to include anti-JCV antibody status as a PML risk factor

Industry news, News / 20 January 2012 / Biogen Idec and Elan Corporation, plc

The U.S. FDA has approved a product label change for TYSABRI…

Elan logo

University College Dublin and Elan announce initiative to create leadership in biotechnology

Industry news, News / 12 December 2011 / Elan Corporation, plc

€3m grant to combine business & science disciplines at University College Dublin…

Professor Christopher Dobson

Cambridge-Elan Centre for Research Innovation and Drug Discovery launched

Industry news, News / 28 November 2011 / F T I Consulting

World’s leading researchers work together on therapeutic advances in neuroscience…

Alkermes to merge with Elan Drug Technologies to create Alkermes plc

Industry news, News / 9 May 2011 / Elan Drug Technologies (EDT)

Alkermes will merge with EDT in a cash and stock transaction currently valued at approximately $960 million…

Elan and Boehringer Ingelheim announce agreement for antibody-based therapeutics

Industry news, News / 9 February 2011 / Boehringer Ingelheim

Announcement covers global technical development and manufacturing for antibody-based therapeutics…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...